Almac Group has announced that its facility in Singapore received a renewal of its GMP/GDP certification following the successful regulatory inspection by the Health Sciences Authority (HSA). This accreditation was awarded after an onsite three-day day inspection held in June 2018.
Headquartered in the UK, Almac is a contract development and manufacturing organisation (CDMO) and operates from locations in the US and Asia Pacific.
Almac's Asia Pacific headquarters and clinical trial supply facility was first established in Singapore in 2015 and expanded the company's offering from within the region to further optimise the clinical supply chain for both global and regional studies in their customers' own language and time zones.
The renewal of the GMP/GDP certification confirms Almac's compliance with the HSA standards of safety, quality and efficacy across its various operations.
"Almac was the first full service clinical trial packaging and distribution organisation to ever receive GMP certification in this region when we opened our Asia-Pacific Headquarters just three years ago," sayd Paul O'Connor, Global VP Quality, Almac Clinical Services. "We are delighted to receive today's official certification which is testament to the quality and skill of our employees," he added.
Almac has reported continued investment to strengthen its in-region capabilities as the company sees the region a key part of its ongoing global expansion strategy to meet market and patient needs.
As part of this strategy, the facility has seen a 40% uplift in business volume, which has led to the creation of further permanent jobs at our Singapore and Japanese facilities in support of this increased demand.
"The successful inspection strengthens Almac's commitment to directly support sponsors conducting regional and global studies by providing clinical manufacturing, packaging, storage, distribution, supply chain management and Interactive Response Technology (IRT)," the company said in a statement.